Innovator国际已开发动力缓冲主动型ETF-4月 IAPR 深 沪
等待开盘 04-02 09:30:00 美东时间
31.98
+0.310
+0.98%
华盛通- 最 高32.115
- 今 开31.96
- 成交量 77.55万股
- 最 低 31.82
- 昨 收 31.67
- 总市值 1.93亿
- 52周最高 32.115
- 市盈率 静 --
- 换手率 12.82%
- 52周最低 26.9559
- 委 比 -85.19%
- 总股本 605.00万
- 历史最高 32.115
- 量 比 8.17
- 振 幅 0.93%
- 历史最低 21.45
- 每 手 1
- 风险率 1.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Healthcare firm Innoviva posts Q2 net income
Overview Innoviva Q2 royalty revenue at $67.3 mln, strong GSK portfolio performance Net product sales rise 54% yr/yr to $35.5 mln, driven by U.S. sales Net income at $63.7 mln, up from a $34.7 mln los...
2025-08-07 04:29
Innoviva Inc. Reports Q2 2025 Results: Net Income Surges to $63.7M, EPS at $1.01, U.S. Net Product Sales Up 54%
Innoviva Inc. (NASDAQ: INVA), a diversified holding company, reported its financial results for the second quarter of 2025, highlighting significant developments and achievements. The company recorded...
2025-08-07 04:05
BRIEF-Briacell Therapeutics’ Subsidiary, BriaPro, Files Patent Application For Immuno-Oncology Platform With Novel Multitargeting Agents
July 29 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL’S SUBSIDIARY, BRIAPRO, FILES PATENT APPLICATION FOR IMMUNO-ONCOLOGY PLATFORM WITH NOVEL MULTITARGETING AGENTS Source text: ID:nGNXbdCRFY...
2025-07-29 19:41
Innoviva Inc. Reports Q1 2025 Results: Revenue Hits $91.6M, Net Loss of $46.6M, EPS Decline to ($0.74)
Innoviva, Inc. (NASDAQ: INVA) reported its financial results for the first quarter ending March 31, 2025. The company recorded gross royalty revenue of $61.3 million from Glaxo Group Limited, slightly...
2025-05-08 04:09
Gain Therapeutics Inc. to Present at IAPRD World Congress on Parkinson's Disease and Related Disorders
Gain Therapeutics, Inc., a clinical-stage biotechnology company, will present at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease ...
2025-04-30 19:45
